Mativ Holdings, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
Several American Century entities and the Stowers Institute for Medical Research have collectively increased their beneficial ownership of Mativ Holdings, Inc. common stock to over 5.6%.
NYSE
Vanguard Capital Management reports beneficial ownership of 5% of Mativ Holdings Inc. common stock as of March 31, 2026.
NYSE
The Vanguard Group has reported zero beneficial ownership in Mativ Holdings Inc. following an internal realignment that disaggregated its reporting.
NYSE
Boundary Creek Advisors LP and Peter Greatrex have disclosed a 4.0% beneficial ownership stake in Mativ Holdings, Inc., including shares underlying call options.
NYSE
Boundary Creek Advisors LP and Peter Greatrex have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 5.2% in Mativ Holdings, Inc.'s common stock, including shares underlying call options.
NYSE
SCHEDULE 13G/A: Vanguard Group Discloses 6.43% Stake in Mativ Holdings Inc
The Vanguard Group has filed an amended Schedule 13G, reporting a beneficial ownership of 6.43% in Mativ Holdings Inc's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an updated Schedule 13G, reporting a 7.6% beneficial ownership stake in Mativ Holdings, Inc. as of March 31, 2025.
NYSE
Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a reduced beneficial ownership stake of 3.9% in Mativ Holdings, Inc. as of December 31, 2024.
NYSE
BlackRock, Inc. has filed an Amendment No. 17 to its Schedule 13G, reporting beneficial ownership of 18.5% of Mativ Holdings, Inc.'s common stock as of December 31, 2024.
NYSE
The Vanguard Group has filed an Amendment No. 15 to its Schedule 13G, disclosing a 9.78% beneficial ownership stake in Mativ Holdings Inc. as of December 31, 2024.